Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds

References

• Agundez JA, Garcia-Martin E, Alonso-Navarro H, Jimenez-Jimenez FJ. 2013. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol. 9 (7):859–874.
   PubMed Web of Science ®Google Scholar
• Bar Am O, Amit T, Youdim MB. 2004. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 355 (3):169–172.
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. 2010. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem. 112 (5):1131–1137.
   PubMed Web of Science ®Google Scholar
• Barreto GE, Iarkov A, Moran VE. 2014. Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front Aging Neurosci. 6:340.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Hukkanen J, and Jacob P. 3rd, 2009. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 192:29–60.
   PubMedGoogle Scholar
• Berthou F, Ratanasavanh D, Alix D, Carlhant D, Riche C, Guillouzo A. 1988. Caffeine and theophylline metabolism in newborn and adult human hepatocytes; comparison with adult rat hepatocytes. Biochem Pharmacol. 37(19):3691–3700.
   PubMed Web of Science ®Google Scholar
• Berthou F, Ratanasavanh D, Riche C, Picart D, Voirin T, Guillouzo A. 1989. Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica. 19(4):401–417.
   PubMed Web of Science ®Google Scholar
• Bianco G, Abate S, Labella C, Cataldi TR. 2009. Identification and fragmentation pathways of caffeine metabolites in urine samples via liquid chromatography with positive electrospray ionization coupled to a hybrid quadrupole linear ion trap(LTQ) and Fourier transform ion cyclotron resonance mass spectrometry and tandem mass spectrometry. Rapid Commun Mass Spectrom. 23 (7):1065–1074.
   PubMed Web of Science ®Google Scholar
• Bier D, Hartmann R, Holschbach M. 2013. Collision-induced dissociation studies of caffeine in positive electrospray ionisation mass spectrometry using six deuterated isotopomers and one N1-ethylated homologue. Rapid Commun Mass Spectrom. 27(8):885–895.
   PubMed Web of Science ®Google Scholar
• Bonomi RE, Laws M, Popov V, Kamal S, Potukutchi S, Shavrin A, Lu X, Turkman N, Liu RS, Mangner T, et al. 2018. A Novel Substrate Radiotracer for Molecular Imaging of SIRT2 Expression and Activity with Positron Emission Tomography. Mol Imaging Biol. 20(4):594–604.
   PubMed Web of Science ®Google Scholar
• Brandange S, Lindblom L. 1979. Enzyme Aldehyde Oxidase Is an Iminium Oxidase - Reaction with Nicotine Delta-1'(5')Iminium Ion. Biochem Biophys Res Commun. 91(3):991–996.
   PubMed Web of Science ®Google Scholar
• Campbell ME, Grant DM, Inaba T, Kalow W. 1987. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos. 15(2):237–249.
   PubMed Web of Science ®Google Scholar
• Chau KY, Cooper JM, Schapira AH. 2010. Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells. Neurochem Int. 57(5):525–529.
   PubMed Web of Science ®Google Scholar
• Chen K, Chen X. 2010. Design and development of molecular imaging probes. Curr Top Med Chem. 10(12):1227–1236.
   PubMed Web of Science ®Google Scholar
• Chênevert R, Mohammadi-Ziarani G, Caron D, Dasser M. 1999. Chemoenzymatic enantioselective synthesis of (-)-enterolactone. Can J Chem. 77(2):223–226.
   Web of Science ®Google Scholar
• Davie CA. 2008. A review of Parkinson's disease. Br Med Bull. 86:109–127.
   PubMed Web of Science ®Google Scholar
• de Biase S, Merlino G, Lorenzut S, Valente M, Gigli GL. 2014. ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. Expert Opin Drug Metab Toxicol. 10(10):1365–1380.
   PubMed Web of Science ®Google Scholar
• Deftereos SN, Dodou E, Andronis C, Persidis A. 2012. From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors. Expert Rev Clin Pharmacol. 5(4):413–425.
   PubMed Web of Science ®Google Scholar
• Dimpfel W, Hoffmann JA. 2011. Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro. BMC Pharmacol. 11:2.
   PubMedGoogle Scholar
• Ferrero JL, Neims AH. 1983. Metabolism of caffeine by mouse liver microsomes: GSH or cytosol causes a shift in products from 1,3,7-trimethylurate to a substituted diaminouracil. Life Sci. 33(12):1173–1178.
   PubMed Web of Science ®Google Scholar
• Forno LS. 1996. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol. 55(3):259–272.
   PubMed Web of Science ®Google Scholar
• Grant DM, Campbell ME, Tang BK, Kalow W. 1987. Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. Biochem Pharmacol. 36(8):1251–1260.
   PubMed Web of Science ®Google Scholar
• Hecht SS, Hochalter JB, Villalta PW, Murphy SE. 2000. 2'-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc Natl Acad Sci U S A. 97(23):12493–12497.
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. 1992. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 42(6):1142–1146.
   PubMedGoogle Scholar
• Hughes AJ, Daniel SE, Lees AJ. 2001. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 57(8):1497–1499.
   PubMed Web of Science ®Google Scholar
• Jacobson O, Kiesewetter DO, Chen X. 2015. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 26(1):1–18.
   PubMed Web of Science ®Google Scholar
• Jia L, Liu X. 2007. The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab. 8(8):822–829.
   PubMed Web of Science ®Google Scholar
• Kakish J, Allen KJ, Harkness TA, Krol ES, Lee JS. 2016. Novel Dimer Compounds That Bind α-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing α-Synuclein. A Possible Prevention Strategy for Parkinson's Disease . ACS Chem Neurosci. 7(12):1671–1680.
   PubMed Web of Science ®Google Scholar
• Kakish J, Lee D, Lee JS. 2015. Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic? ACS Chem Neurosci. 6(12):1930–1940.
   PubMed Web of Science ®Google Scholar
• Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, et al. 1998. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 55(7):969–978.
   PubMed Web of Science ®Google Scholar
• Medana C, Santoro V, Dal Bello F, Sala C, Pazzi M, Sarro M, Calza P. 2016. Mass spectrometric fragmentation and photocatalytic transformation of nicotine and cotinine. Rapid Commun Mass Spectrom. 30(24):2617–2627.
   PubMed Web of Science ®Google Scholar
• Mendes VM, Coelho M, Tome AR, Cunha RA, Manadas B. 2019. Validation of an LC-MS/MS Method for the Quantification of Caffeine and Theobromine Using Non-Matched Matrix Calibration Curve. Molecules. 24(16):2863.
   PubMed Web of Science ®Google Scholar
• Mukai M, Uchimura T, Zhang X, Greene D, Vergeire M, Cantillon M. 2018. Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects. J Clin Pharmacol. 58(2):193–201.
   PubMed Web of Science ®Google Scholar
• Murphy PJ. 1973. Enzymatic oxidation of nicotine to nicotine 1'(5') iminium ion. A newly discovered intermediate in the metabolism of nicotine. J Biol Chem. 248(8):2796–2800.
   PubMed Web of Science ®Google Scholar
• Nwabufo CK, El-Aneed A, Krol ES. 2019. Tandem mass spectrometric analysis of novel caffeine scaffold-based bifunctional compounds for Parkinson's disease. Rapid Commun Mass Spectrom. 33(23):1792–1803.
   PubMed Web of Science ®Google Scholar
• Park BK, Kitteringham NR. 1994. Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implications. Drug Metab Rev. 26(3):605–643.
   PubMed Web of Science ®Google Scholar
• Patil SP, Jain PD, Ghumatkar PJ, Tambe R, Sathaye S. 2014. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience. 277:747–754.
   PubMed Web of Science ®Google Scholar
• Peterson LA, Trevor A, Castagnoli N. Jr., 1987. Stereochemical studies on the cytochrome P-450 catalyzed oxidation of (S)-nicotine to the (S)-nicotine delta 1'(5')-iminium species. J Med Chem. 30(2):249–254.
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, et al. 2012. Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology. 79(7):651–658.
   PubMed Web of Science ®Google Scholar
• Prediger RD. 2010. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms. J Alzheimers Dis. 20 Suppl 1(Suppl 1):S205–S220.
   PubMedGoogle Scholar
• Quik M. 2004. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27(9):561–568.
   PubMed Web of Science ®Google Scholar
• Quik M, Perez XA, Bordia T. 2012. Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord. 27(8):947–957.
   PubMed Web of Science ®Google Scholar
• Rajput AH, Rozdilsky B, Rajput A. 1991. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci. 18(3):275–278.
   PubMed Web of Science ®Google Scholar
• Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. 2016. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 86(6):566–576.
   PubMed Web of Science ®Google Scholar
• Ross GW, Petrovitch H. 2001. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging. 18(11):797–806.
   PubMed Web of Science ®Google Scholar
• Samii A, Nutt JG, Ransom BR. 2004. Parkinson's disease. Lancet. 363(9423):1783–1793.
   PubMed Web of Science ®Google Scholar
• Schrag A, Ben-Shlomo Y, Quinn N. 2002. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. 73(5):529–534.
   PubMed Web of Science ®Google Scholar
• Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J. 1998. N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. Journal of Neural Transmission. Supplementa. 52:301–305.
   PubMedGoogle Scholar
• Temporal KH, Scott KS, Mohr ALA, Logan BK. 2017. Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine. J Anal Toxicol. 41(7):646–657.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Gaig C, Santamaría J, Compta Y. 2009. Diagnosis and the premotor phase of Parkinson disease. Neurology. 72(7 Suppl):S12–S20.
   PubMedGoogle Scholar
• Uversky VN. 2008. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci. 9(5):507–540.
   PubMed Web of Science ®Google Scholar
• Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. 2012. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 18(6):753–758.
   PubMed Web of Science ®Google Scholar
• Wang T, Yang L, Hua J, Xie H, Jiang X, Wang L. 2016. Simultaneous bioanalysis of rasagiline and its major metabolites in human plasma by LC-MS/MS: Application to a clinical pharmacokinetic study. J Pharm Biomed Anal. 125:280–285.
   PubMed Web of Science ®Google Scholar